An Efficacy and Safety Study of Ravulizumab in ALS Participants
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Orange, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Alexion Pharmaceuticals
- ID
- NCT04248465
- Phase
- Phase 3
- Study Type
- Interventional
- Last Updated